ZA200703509B - Pharmaceutical formulation comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty acids (PUFA) - Google Patents
Pharmaceutical formulation comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty acids (PUFA)Info
- Publication number
- ZA200703509B ZA200703509B ZA200703509A ZA200703509A ZA200703509B ZA 200703509 B ZA200703509 B ZA 200703509B ZA 200703509 A ZA200703509 A ZA 200703509A ZA 200703509 A ZA200703509 A ZA 200703509A ZA 200703509 B ZA200703509 B ZA 200703509B
- Authority
- ZA
- South Africa
- Prior art keywords
- pufa
- microcapsules
- fatty acids
- alkyl esters
- polyunsaturated fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200402492A ES2255426B1 (es) | 2004-10-19 | 2004-10-19 | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200703509B true ZA200703509B (en) | 2008-09-25 |
Family
ID=36227494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200703509A ZA200703509B (en) | 2004-10-19 | 2005-10-13 | Pharmaceutical formulation comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty acids (PUFA) |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20090196920A1 (es) |
| EP (1) | EP1803440B1 (es) |
| JP (1) | JP4976302B2 (es) |
| KR (1) | KR101413339B1 (es) |
| CN (2) | CN102727462A (es) |
| AT (1) | ATE469641T1 (es) |
| AU (1) | AU2005298587B2 (es) |
| BR (1) | BRPI0516152A (es) |
| CA (1) | CA2583756C (es) |
| CY (1) | CY1110751T1 (es) |
| DE (1) | DE602005021668D1 (es) |
| DK (1) | DK1803440T3 (es) |
| EA (1) | EA012371B1 (es) |
| ES (2) | ES2255426B1 (es) |
| IL (1) | IL182466A (es) |
| MX (1) | MX2007004655A (es) |
| NZ (1) | NZ554265A (es) |
| PL (1) | PL1803440T3 (es) |
| PT (1) | PT1803440E (es) |
| SI (1) | SI1803440T1 (es) |
| WO (1) | WO2006045865A1 (es) |
| ZA (1) | ZA200703509B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200745026A (en) | 2005-12-13 | 2007-12-16 | Teva Pharma | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| DK2018153T3 (da) | 2006-04-26 | 2012-07-23 | Rosemont Pharmaceuticals Ltd | Flydende orale sammensætninger |
| WO2008000731A2 (en) * | 2006-06-26 | 2008-01-03 | Valpharma S.A. | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids |
| KR20090017668A (ko) * | 2006-07-06 | 2009-02-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 제어된 약동학을 갖는 조성물 |
| ITMI20072142A1 (it) | 2007-11-08 | 2009-05-09 | Yervant Zarmanian | Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3 |
| GB0724735D0 (en) | 2007-12-19 | 2008-01-30 | Psynova Neurotech Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
| EP2229939A4 (en) * | 2008-01-10 | 2011-04-27 | Takeda Pharmaceutical | CAPSULE FORMULATION |
| GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
| GB0818472D0 (en) * | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
| ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
| NZ789295A (en) | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| ES2363965B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm S.A. | Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados. |
| ES2364011B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| ES2363964B1 (es) * | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
| KR20120104270A (ko) * | 2009-12-23 | 2012-09-20 | 데피안떼 파마슈띠까 에스.에이. | 심혈관계 질환 치료에 유용한 복합 조성물 |
| CA3065589C (en) * | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
| CA2706270C (en) | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
| WO2012002464A1 (ja) | 2010-06-30 | 2012-01-05 | 持田製薬株式会社 | ω３脂肪酸の配合製剤 |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물 |
| WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| KR101466617B1 (ko) * | 2011-11-17 | 2014-11-28 | 한미약품 주식회사 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
| EP2846779A4 (en) * | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
| AU2013264518B2 (en) | 2012-05-22 | 2016-02-11 | Kuhnil Pharm. Co., Ltd. | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |
| CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
| KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
| WO2014182003A1 (en) * | 2013-05-06 | 2014-11-13 | Hanmi Pharm. Co., Ltd. | Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof |
| WO2015185240A1 (en) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |
| RU2614734C2 (ru) * | 2015-05-21 | 2017-03-28 | Татьяна Алексеевна Денисюк | Способ получения нанокапсул розувастатина в каррагинане |
| KR101950907B1 (ko) * | 2016-02-05 | 2019-02-21 | 한국유나이티드제약 주식회사 | 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제 |
| WO2019143981A1 (en) * | 2018-01-19 | 2019-07-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
| CN112218630A (zh) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | 降低受试者的心血管事件的风险的方法 |
| WO2022129002A1 (en) * | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Coarse dispersion comprising statin and vitamin e oil |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5312473B1 (es) | 1971-05-24 | 1978-05-01 | ||
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| US5035896A (en) | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| EP1162954A1 (en) | 1999-03-31 | 2001-12-19 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
| EP1165141A2 (en) | 1999-03-31 | 2002-01-02 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
| US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
| AU3651102A (en) * | 2000-11-29 | 2002-06-11 | Smithkline Beecham Corp | Composition containing statins and calcium for improved cardiovascular health |
| CA2450238A1 (en) * | 2001-06-12 | 2002-12-19 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
| EP1413315A4 (en) * | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
| CA2488499C (en) * | 2002-06-10 | 2013-03-19 | Elan Pharma International Ltd. | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| CA2499501A1 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| WO2004084870A1 (en) * | 2003-03-28 | 2004-10-07 | Sigmoid Biotechnologies Limited | Solid oral dosage form containing seamless microcapsules |
-
2004
- 2004-10-19 ES ES200402492A patent/ES2255426B1/es not_active Expired - Fee Related
-
2005
- 2005-10-13 PT PT05802903T patent/PT1803440E/pt unknown
- 2005-10-13 ZA ZA200703509A patent/ZA200703509B/xx unknown
- 2005-10-13 KR KR1020077008798A patent/KR101413339B1/ko not_active IP Right Cessation
- 2005-10-13 WO PCT/ES2005/000542 patent/WO2006045865A1/es active Application Filing
- 2005-10-13 EP EP05802903A patent/EP1803440B1/en not_active Not-in-force
- 2005-10-13 AU AU2005298587A patent/AU2005298587B2/en not_active Ceased
- 2005-10-13 DK DK05802903.4T patent/DK1803440T3/da active
- 2005-10-13 MX MX2007004655A patent/MX2007004655A/es active IP Right Grant
- 2005-10-13 NZ NZ554265A patent/NZ554265A/en not_active IP Right Cessation
- 2005-10-13 US US11/665,665 patent/US20090196920A1/en not_active Abandoned
- 2005-10-13 JP JP2007537313A patent/JP4976302B2/ja not_active Expired - Fee Related
- 2005-10-13 DE DE602005021668T patent/DE602005021668D1/de active Active
- 2005-10-13 EA EA200700614A patent/EA012371B1/ru not_active IP Right Cessation
- 2005-10-13 BR BRPI0516152-5A patent/BRPI0516152A/pt active Search and Examination
- 2005-10-13 PL PL05802903T patent/PL1803440T3/pl unknown
- 2005-10-13 CN CN2012100736124A patent/CN102727462A/zh active Pending
- 2005-10-13 ES ES05802903T patent/ES2347055T3/es active Active
- 2005-10-13 CN CNA2005800357056A patent/CN101043873A/zh active Pending
- 2005-10-13 AT AT05802903T patent/ATE469641T1/de active
- 2005-10-13 SI SI200531074T patent/SI1803440T1/sl unknown
- 2005-10-13 CA CA2583756A patent/CA2583756C/en not_active Expired - Fee Related
-
2007
- 2007-04-11 IL IL182466A patent/IL182466A/en not_active IP Right Cessation
-
2010
- 2010-08-30 CY CY20101100790T patent/CY1110751T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL182466A (en) | 2013-06-27 |
| ATE469641T1 (de) | 2010-06-15 |
| ES2255426B1 (es) | 2007-08-16 |
| SI1803440T1 (sl) | 2010-10-29 |
| DE602005021668D1 (de) | 2010-07-15 |
| AU2005298587A1 (en) | 2006-05-04 |
| ES2347055T3 (es) | 2010-10-25 |
| CY1110751T1 (el) | 2015-06-10 |
| EA200700614A1 (ru) | 2007-10-26 |
| MX2007004655A (es) | 2008-03-10 |
| ES2255426A1 (es) | 2006-06-16 |
| IL182466A0 (en) | 2007-07-24 |
| JP4976302B2 (ja) | 2012-07-18 |
| PL1803440T3 (pl) | 2010-12-31 |
| PT1803440E (pt) | 2010-08-31 |
| WO2006045865A1 (es) | 2006-05-04 |
| KR20070083715A (ko) | 2007-08-24 |
| US20090196920A1 (en) | 2009-08-06 |
| CN101043873A (zh) | 2007-09-26 |
| CA2583756A1 (en) | 2006-05-04 |
| AU2005298587B2 (en) | 2010-08-05 |
| JP2008517040A (ja) | 2008-05-22 |
| EP1803440B1 (en) | 2010-06-02 |
| KR101413339B1 (ko) | 2014-06-27 |
| NZ554265A (en) | 2010-12-24 |
| EA012371B1 (ru) | 2009-10-30 |
| EP1803440A1 (en) | 2007-07-04 |
| BRPI0516152A (pt) | 2008-08-26 |
| DK1803440T3 (da) | 2010-10-04 |
| CA2583756C (en) | 2013-12-24 |
| CN102727462A (zh) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200703509B (en) | Pharmaceutical formulation comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty acids (PUFA) | |
| PT1773312E (pt) | Composição contendo estatinas e ácidos graxos ómega-3 | |
| EP2602308A3 (en) | Lipase-catalysed esterification of marine oil | |
| UY29194A1 (es) | Composiciones de aceites ricos en acidos grasos poliinsaturados (pufa) | |
| PL2436275T3 (pl) | Kompozycja lipidowa dla poprawy funkcji mózgu | |
| EP1801096B8 (en) | Polyglycerol fatty acid ester and composition containing same | |
| EP2089014A4 (en) | OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC AGENT FOR REDUCING APO-B LEVELS | |
| ATE348140T1 (de) | Lipasekatalysierte veresterung von fischoel | |
| BRPI0418921A (pt) | uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição | |
| BRPI0705244A (pt) | composição oleosa de ácido linolênico conjugado | |
| EP1578389A4 (en) | COMPOSITIONS COMPRISING AT LEAST ONE OIL STRUCTURED WITH AT LEAST ONE SILICON POLYAMIDE POLYMER AND AT LEAST ONE SHORT CHAIN ESTER AND USE METHOD THEREFOR | |
| BR0209749A (pt) | Coenzima q e epa ou outro ácido graxo essencial | |
| WO2008011468A8 (en) | Fatty acid desaturases from tetraselmis suecica | |
| NO20055784D0 (no) | Fremstilling av polyumettede fettsyrer i oljesyrenk gjaer | |
| DK1135996T3 (da) | Anvendelse af syntetiske triglycerider på basis af konjugeret linolsyre som farvestabilisator i levnedsmidler | |
| DE60212786D1 (de) | Verwendung von polyungesättigten Fettsäuren zur primären Vorbeugung von kardiovaskulären Anfällen | |
| EP2679687A3 (en) | Fatty acid blends and uses therefor | |
| EP2510927A3 (en) | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage | |
| BRPI0416403A (pt) | composição de óleo enriquecida em diglicerìdeo com ácido linoléico conjugado | |
| ATE422350T1 (de) | Anisinsäure und glyceride enthaltende zusammensetzungen | |
| ATE443515T1 (de) | Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung | |
| TR199801519T2 (xx) | Yenebilir bitkisel ya� bile�imi. | |
| EP1718156A4 (en) | COMPOSITIONS AND METHODS FOR ALTERING POLYUNSATURATED FATTY ACID CONTENT OF BIOLOGICAL CELLS | |
| AU2003222739A1 (en) | A facile two-step enzyme process for increasing the content of polyunsaturated fatty acids in fish oil | |
| DE60101859D1 (de) | Pinolensäure gegen Diabetes |